Kearney Brian P, Sayre John R, Flaherty John F, Chen Shan-Shan, Kaul Sanjeev, Cheng Andrew K
Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404, USA.
J Clin Pharmacol. 2005 Dec;45(12):1360-7. doi: 10.1177/0091270005281351.
The drug-drug and drug-food interactions between tenofovir DF and didanosine EC were evaluated in 2 pharmacokinetic studies in healthy adult subjects. When 400 mg was dosed with tenofovir DF, mean didanosine AUC was increased by 44% to 60% following fasted or fed administration. Staggered coadministration (2 hour, fasted) of a reduced didanosine dose of 250 mg resulted in equivalent didanosine exposure, while simultaneous administration with tenofovir DF in the fasted and fed state resulted in didanosine AUCs similar to that of the reference treatment of 400 mg alone in the fasted state. These data indicate that a dose reduction of didanosine is warranted when it is used with tenofovir DF. The drug-drug-food interaction of didanosine may offer more flexible dosing of didanosine EC when it is used with tenofovir DF. Patients receiving tenofovir DF and didanosine together should be carefully monitored for safety and efficacy.
在两项针对健康成年受试者的药代动力学研究中,对替诺福韦酯与去羟肌苷肠溶胶囊之间的药物-药物及药物-食物相互作用进行了评估。当与400mg替诺福韦酯合用时,无论空腹或进食状态下给药,去羟肌苷的平均药时曲线下面积(AUC)均增加44%至60%。错开服用降低剂量至250mg的去羟肌苷(空腹,间隔2小时)可使去羟肌苷暴露量相当,而在空腹和进食状态下与替诺福韦酯同时给药时,去羟肌苷的AUC与仅在空腹状态下单独给予400mg的参比治疗相似。这些数据表明,去羟肌苷与替诺福韦酯合用时需要降低剂量。去羟肌苷的药物-药物-食物相互作用可能为其与替诺福韦酯合用时提供更灵活的去羟肌苷肠溶胶囊给药方案。同时接受替诺福韦酯和去羟肌苷治疗的患者应密切监测安全性和疗效。